On the one hand, by reducing the substrate for prion conversion and the receptor for neurotoxicity, this proteolytic release of almost full length PrPC from the plasma membrane could be protective with regard to prion diseases (Marella et al., 2002; Heiseke et al., 2008; Altmeppen et al., 2012). This evidence concerns the gene PRNP and prion disease.